Cassava Sciences Q1 2025: Assets Surge, Net Loss Widens
Ticker: FLNA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | high |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials, R&D
TL;DR
**Cassava Sciences Q1 2025: Assets jump to $120M, but net loss hits $48.2M. R&D burn continues.**
AI Summary
Cassava Sciences Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial statements show minimal revenue, with $0.001 million in both current and prior year periods. Total assets stood at $120 million as of March 31, 2025, a significant increase from $48.3 million at the end of 2023. The company also reported a net loss of $48.2 million for the three months ended March 31, 2025.
Why It Matters
The substantial increase in assets suggests significant investment or financing activities, while the widening net loss highlights the ongoing costs associated with the company's research and development efforts.
Risk Assessment
Risk Level: high — The company has a significant net loss and minimal revenue, indicating a high burn rate and reliance on external funding for its research and development activities.
Key Numbers
- $120.0M — Total Assets (As of March 31, 2025, showing a significant increase.)
- $48.2M — Net Loss (For the three months ended March 31, 2025, indicating ongoing operational costs.)
- $0.001M — Revenue (For the three months ended March 31, 2025, reflecting minimal sales.)
Key Players & Entities
- Cassava Sciences Inc. (company) — Filer of the 10-Q report.
- 20250331 (date) — End of the reporting period for the 10-Q.
- $120,000,000 (dollar_amount) — Total assets as of March 31, 2025.
- $48,203,179 (dollar_amount) — Net loss for the three months ended March 31, 2025.
- PAIN THERAPEUTICS INC (company) — Former company name.
FAQ
What is the primary driver for the increase in total assets to $120 million as of March 31, 2025?
The filing does not explicitly detail the drivers for the increase in total assets to $120 million, but it represents a substantial rise from $48.3 million at the end of 2023.
What is the net loss for the first quarter of 2025?
The net loss for the three months ended March 31, 2025, was $48,203,179.
What was the company's revenue for the first quarter of 2025?
Revenue for the three months ended March 31, 2025, was $0.001 million, the same as the prior year period.
When did Cassava Sciences Inc. change its name from PAIN THERAPEUTICS INC?
The company changed its name from PAIN THERAPEUTICS INC on March 9, 2000.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding CASSAVA SCIENCES INC (FLNA).